AFT Pharmaceuticals (NZSE:AFT) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NZSE:AFT AFT Pharmaceuticals Ltd NZSE:AFT
95 GF Score
Price NZ$3.94
GF Value NZ$4.18
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is AFT Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

NZSE:AFT vs ZTS, UTHR, VTRS: Short Interest Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AFT Pharmaceuticals Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where AFT Pharmaceuticals's Short Interest falls into.


NZSE:AFT
95GF Score
AFT Pharmaceuticals Ltd NZSE:AFT
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AFT Pharmaceuticals (NZSE:AFT) Overvalued in 2026?

Based on GuruFocus' analysis, AFT Pharmaceuticals stock appears to be undervalued. The current stock price of NZ$3.94 is trading 5.7% below its estimated GF Value™ of NZ$4.18. GuruFocus considers AFT Pharmaceuticals to be Fairly Valued.

Key valuation signals for NZSE:AFT:

  • Short Interest:
  • GF Value™: NZ$4.18 vs. price of NZ$3.94 (5.7% below fair value)
  • GF Score™: 95/100 with 4 warning signs

No single metric tells the full story. See the NZSE:AFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AFT Pharmaceuticals Business Description

Other Exchanges AFP:Australia
Address 129 Hurstmere Road, Level 1, Takapuna, Auckland, NTL, NZL, 0622
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
95GF Score

Get the complete analysis for NZSE:AFT

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NZ$3.94
Price
NZ$4.18
GF Value